EPM2A and adult polyglucosan body disease: Other promising approaches include EPM2A gene replacement, removal of PBs by bioengineered hydrolases, and the use of an autophagic activator with an FDA orphan designation for the treatment of APBD (Brewer et al, 2019; Kakhlon et al, 2021; Zafra-Puerta et al, 2024).